Table 2 |
|||||
|
Published interventional clinical trials using endothelial progenitor cells. |
|||||
|
Disease |
Patient numbers |
Intervention |
Description |
Results |
Reference |
|
|
|||||
|
Chronic ischemic heart disease |
121 |
Transcoronary transplantation of bone marrow-derived progenitor cells |
Intracoronary infusion in patients with chronic ischemic heart disease |
Reduced serum levels of heart failure markers; reduced mortality |
[101] |
|
Idiopathic pulmonary arterial hypertension |
33 |
Transplantation of autologous EPCs (differentiated from peripheral blood mononuclear cells) |
Test safety, feasibility, and initial clinical outcome of intravenous infusion of autologous EPCs in patients with idiopathic pulmonary arterial hypertension |
Feasible and safe infusion of autologous EPCs is beneficial to exercise capacity and pulmonary hemodynamics in patients with idiopathic pulmonary arterial hypertension |
[102] |
|
Chronic ischemic heart disease |
75 |
Intracoronary infusion of peripheral blood-EPCs and bone marrow-derived progenitor cells |
Effect of intracoronary EPC infusion on the left ventricular contractile function |
Feasible and safe transplantation of bone marrow-derived progenitor cells is associated with moderate but significant improvement in the left ventricular ejection fraction after three months |
[103] |
|
Acute myocardial infarction |
26 |
Intracoronary injection of EPCs (differentiated from peripheral blood mononuclear cells) |
Effect of intracoronary EPC infusion on coronary vasomotion and left ventricular function in patients after recanalization of chronic coronary total occlusion |
Increased left ventricular ejection fraction, coronary flow reserve; reduction in infarct size |
[104] |
|
Acute myocardial infarction |
11 |
Transcoronary transplantation of bone marrow-derived EPCs and mesenchymal stem cells |
Effect of transcoronary transplantation of EPCs and mesenchymal stem cells on myocardial contractility and tissue regeneration |
Reduction in infarct size |
[105] |
|
Acute myocardial infarction |
59 |
Intracoronary infusion of peripheral blood EPCs and bone marrow-derived progenitor cells |
Effect of intracoronary EPC infusion on left ventricular function, infarct size and reactive hypertrophy |
Increased left ventricular ejection fraction, no reactive hypertrophy; Reduction in infarct size |
[106] |
|
Critical limb ischemia |
28 |
Intramuscular injections of peripheral blood granulocyte colony stimulating factor mobilized CD34+ CD133+ EPCs |
Effect of intramuscular infusion on and limb salvage rate for amputation at 12 months |
Implantation of EPCs in critical limb ischemia is a safe alternative, improves tissue perfusion, and obtains high amputation-free rates |
[107] |
|
Acute myocardial infarction |
366 |
EPC capture stent |
Safety and efficacy of EPC capture stents in the acute myocardial infarction settings |
EPC stent is safe; At two-year follow-up, the EPC group showed favorable target vessel revascularizations rate and stent thrombosis remained a low-event occurrence |
[108] |
|
ST elevation acute myocardial infarction |
100 |
EPC capture stent |
Safety and efficacy of EPC capture stents in the ST elevation acute myocardial infarction settings |
The study does not support the use of EPC capture stents with short duration dual antiplatelet therapy in patients with ST elevation acute myocardial infarction |
[109] |
|
Refractory angina |
167 |
Intramyocardial injections of autologous CD34+ cells |
Effect of intramyocardial injections of autologous CD34+ cells on refractory angina patient |
Intramyocardial injections of autologous CD34+ cells improves angina frequency and exercise tolerance |
[110] |
|
|
|||||
|
EPC: endothelial progenitor cell. |
|||||
|
Caiado and Dias Fibrogenesis & Tissue Repair 2012 5:4 doi:10.1186/1755-1536-5-4 |
|||||
